Report Content
Chapter 1 Delivery Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Gene therapy industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Vector trends
2.1.4 Delivery method trends
2.1.5 Gene type trends
2.1.6 Indication trends
Chapter 3 Gene Therapy Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising investments in research and development for gene therapy
3.2.1.2 Increasing number of product approval and launches
3.2.1.3 Technological advancements in gene therapy
3.2.1.4 Growing prevalence of cancer, genetic and rare diseases
3.2.1.5 Increasing adoption of personalized medicine
3.2.2 Industry pitfalls & challenges
3.2.2.1 High costs of gene therapy treatment
3.2.2.2 Lack of standard regulations
3.3 Growth potential analysis
3.3.1 By vector
3.3.2 By delivery method
3.3.3 By gene type
3.3.4 By indication
3.4 COVID- 19 impact analysis
3.5 Clinical trial data analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategy dashboard, 2022
4.6 Strategic outlook matrix, 2022
Chapter 5 Gene Therapy Market Size and Forecast, By Vector (USD Million)
5.1 Key trends, by vector
5.2 Viral vectors
5.2.1 Retro viral vectors
5.2.1.1 Replication-competent vectors
5.2.1.2 Replication-defective vectors
5.2.2 Adeno-associated virus vectors
5.2.3 Lentiviral vectors
5.2.4 Other viral vectors
5.3 Non-viral vectors
5.3.1 Oligonucleotides
5.3.2 Other non-viral vectors
Chapter 6 Gene Therapy Market Size and Forecast, By Delivery Method (USD Million)
6.1 Key trends, by delivery method
6.2 In vivo gene therapy
6.3 Ex vivo gene therapy
Chapter 7 Gene Therapy Market Size and Forecast, By Gene type (USD Million)
7.1 Key trends, by gene type
7.2 Antigen
7.3 Cytokine
7.4 Tumor suppressor
7.5 Suicide
7.6 Deficiency
7.7 Growth factors
7.8 Receptors
7.9 Other gene types
Chapter 8 Gene Therapy Market Size and Forecast, By Indication (USD Million)
8.1 Key trends, by gene type
8.2 Cancer
8.2.1 Acute lymphoblastic leukemia (ALL)
8.2.2 Large B-cell lymphoma
8.2.3 Head & neck squamous cell carcinoma
8.2.4 Melanoma (Lesions)
8.3 Neurological diseases
8.4 DMD (Duchenne Muscular Dystrophy)
8.5 Hepatological diseases
8.6 Inherited retinal disease
8.7 Peripheral arterial disease
8.8 Other indications
Chapter 9 Gene Therapy Market Size and Forecast, By Region (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Switzerland
9.3.7 Netherlands
9.3.8 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Merck KGaA
10.2 REGENXBIO, Inc.
10.3 Oxford Biomedica
10.4 Dimension Therapeutics, Inc.
10.5 Bristol-Myers Squibb Company
10.6 SANOFI
10.7 Applied Genetic Technologies Corporation
10.8 F. Hoffmann-La Roche Ltd
10.9 bluebird bio, Inc
10.10 Novartis AG
10.11 Orchard Therapeutics
10.12 Gilead Lifesciences, Inc.
10.13 BENITEC BIOPHARMA
10.14 SIBIONO
10.15 Shanghai Sunway Biotech Co., Ltd.
